MARKET

NVRO

NVRO

Nevro Corp
NYSE
14.22
-0.34
-2.34%
After Hours: 14.22 0 0.00% 16:02 03/01 EST
OPEN
14.59
PREV CLOSE
14.56
HIGH
14.61
LOW
14.13
VOLUME
457.58K
TURNOVER
0
52 WEEK HIGH
39.68
52 WEEK LOW
13.98
MARKET CAP
517.58M
P/E (TTM)
-5.5486
1D
5D
1M
3M
1Y
5Y
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
NASDAQ · 2d ago
FDA clears Nevro SI joint device without need for lateral screw
Healthcare FDA clears Nevro SI joint device without need for lateral screw. Nevro Corp. Said the FDA has cleared its sacroiliac joint fusion device for marketing without the need to include the lateral screw . The device will be marketed under the name Nevro1.
Seeking Alpha · 3d ago
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
TipRanks · 5d ago
Weekly Report: what happened at NVRO last week (0219-0223)?
Weekly Report · 5d ago
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
Anthony Petrone, an analyst from Mizuho Securities, maintained the Hold rating on Nevro Corp (NVRO – Research Report). The associated price target is $20.00. The company's core Spinal Cord Stimulation business continues to underperform relative to the market.
TipRanks · 5d ago
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Nevro Corp. (NYSE:NVRO) makes use of debt to fund growth. The company has US$211.5m in debt, but has net cash of US$111.3m. Its balance sheet shows that Nevro has a healthy amount of cash on hand. However, the company has a loss-making history and is likely to be more risky. We look at Nevro to see if its debt levels are a cause for concern.
Simply Wall St · 6d ago
Why Nevro Stock Lagged the Market on Thursday
Medical device maker Nevro reports better-than-expected fourth-quarter results. The company's stock price dipped marginally after the report. The S&P 500 index gained nearly 2.5%. Nevro's revenue inched up 2% year over year to $116 million in the fourth quarter.
The Motley Fool · 02/22 23:21
Oppenheimer cuts Nevro to perform, cites weakness in core business
Oppenheimer cuts Nevro to perform, cites weakness in core business. The investment bank says the company has an "unclear path to material growth" in its core spinal cord stimulation business. Nevro Corp. Downgraded to perform by Oppenheimer to perform.
Seeking Alpha · 02/22 17:59
More
About NVRO
Nevro Corp. is a global medical device company. The Company is focused on delivering life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a versatile range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. The Company's products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, Surpass Surgical Lead and Reduced-size Surpass-C Surgical Lead. The Company is also focused on a minimally invasive treatment option for patients suffering from chronic sacroiliac joint (SI Joint) pain.

Webull offers Nevro Corp stock information, including NYSE: NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.